newsfilter
← Latest News
GlobeNewswire·

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H